In this issue:
Avelumab maintenance for advanced/metastatic urothelial carcinoma
Impact of performance status in NSCLC with PD-L1 ≥50% treated with pembrolizumab
Trastuzumab emtansine for HER2-positive breast cancer with brain metastases
Consolidation pembrolizumab following chemoradiation in unresectable stage III NSCLC
Optimal nivolumab duration for pretreated, advanced NSCLC
Immune-checkpoint inhibitors in metastatic gastric/gastroesophageal junction cancers
Pembrolizumab monotherapy for recurrent/metastatic/unresectable cutaneous SCC
Salvage ipilimumab and nivolumab for metastatic RCC after immune checkpoint inhibitors
FOLFOXIRI vs. doublets, both with bevacizumab, in unresectable metastatic colorectal cancer
Please login below to download this issue (PDF)